Scott Gottlieb, MD

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-for...

More FDA departure news from my colleague. FDA's biologics center reported 106 departures from Jan. 1 to June 30. These numbers do not include those who were part of the reduction-in-force. FDA sources estimate CBER lost another 100-150 due to the RIF.
insights.citeline.com/pink-sheet/a...

FDA’s cancer review team overseeing breast and gynecological products has lost about 1/3 of its medical review staff and the malignant heme group will lose about 2/3 of its medical review staff—all to voluntary resignations clustered among seasoned reviewers

insights.citeline.com/pink-sheet/a...

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-for...

From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force

insights.citeline.com/pink-sheet/a...

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-for...

From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force

insights.citeline.com/pink-sheet/a...

FDA’s cancer review team overseeing breast and gynecological products has lost about 1/3 of its medical review staff and the malignant heme group will lose about 2/3 of its medical review staff—all to voluntary resignations clustered among seasoned reviewers

insights.citeline.com/pink-sheet/a...

YouTube video by Face the Nation Dr. Scott Gottlieb on HHS Secretary RFK Jr.'s newly appointed vaccine advisory panel

My segment today on CBS.com Face the Nation on the recent CDC vaccine advisory committee meeting.

YouTube video by Face the Nation Dr. Scott Gottlieb on HHS Secretary RFK Jr.'s newly appointed vaccine advisory panel

My segment today on CBS.com Face the Nation on the recent CDC vaccine advisory committee meeting.

YouTube video by CNBC Television Dr. Scott Gottlieb on CDC's new vaccine advisory board: The consequences will be felt for years

My segment today on cnbc.com on the CDC’s ACIP meeting.

YouTube video by CNBC Television Dr. Scott Gottlieb on CDC's new vaccine advisory board: The consequences will be felt for years

My segment today on cnbc.com on the CDC’s ACIP meeting.

My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA review team enabling these approvals was disbanded, and it may undo that historic progress. @statnews.com

My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA review team enabling these approvals was disbanded, and it may undo that historic progress. @statnews.com

Former FDA commissioner: ‘Cost-cutting’ may undo one of Trump’s best drug pricing achievements The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang for the taxpayers’ buck, writes former FDA Commissioner Scott Gottlieb.

My STAT News Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight that success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress

Former FDA commissioner: ‘Cost-cutting’ may undo one of Trump’s best drug pricing achievements The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang for the taxpayers’ buck, writes former FDA Commissioner Scott Gottlieb.

My STAT News Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight that success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress

How to stop the shift of drug discovery from the U.S. to China U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb explains how to stop the shift.

My op-ed on the large shift of drug discovery moving to China and policy steps the U.S. can take to keep the innovation economy in America. "Five years ago, U.S. drug makers didn’t license any new drugs from China. By 2024, one-third came from Chinese biotech"

How to stop the shift of drug discovery from the U.S. to China U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb explains how to stop the shift.

How to stop the shift of drug discovery from the U.S. to China www.statnews.com/2025/05/06/h... from @scottgottliebmd.bsky.social via @statnews.com

How to stop the shift of drug discovery from the U.S. to China U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb explains how to stop the shift.

My op-ed on the large shift of drug discovery moving to China and policy steps the U.S. can take to keep the innovation economy in America. "Five years ago, U.S. drug makers didn’t license any new drugs from China. By 2024, one-third came from Chinese biotech"

Survey from MassBio and Biocom:

“Of the 88 companies who responded, 50% of respondents reported at least one tangible impact from the FDA's reduction in workforce. This is all within the first 17 days following the RIF.” Reporting via Eric Schmidt of Cantor

Whooping cough cases are rising again in the US Preliminary data from the U.S. Centers of Disease Control and Prevention says the U.S. has seen 8,485 cases of whooping cough in 2025.

Whooping cough cases are rising, and doctors are bracing for another tough year. There have been 8,485 cases reported so far in 2025, according to preliminary data from the CDC. That’s twice as many cases as this time last year.

apnews.com/article/whoo...

Steve Usdin writing in BioCentury: “It’s official: FDA says its cuts are delaying drug regulation — Layoffs, lack of access to journals slow response FDA says”

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs The FDA Reduction-in-Force (Termination)—or “RIF(T)”—announced last week has resulted in countless stories in the press and on personal LinkedIn accounts from those RIF’d.  As the dust begins to se…

This FDA office enabled all of the first time generic drug approvals in the U.S. Their work helped substantially lower drug costs and increase competition during President Trump’s first term, including spearheading approval of the first generic EpiPen in 2018. This office has now been eliminated

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs The FDA Reduction-in-Force (Termination)—or “RIF(T)”—announced last week has resulted in countless stories in the press and on personal LinkedIn accounts from those RIF’d.  As the dust begins to se…

This FDA office enabled all of the first time generic drug approvals in the U.S. Their work helped substantially lower drug costs and increase competition during President Trump’s first term, including spearheading approval of the first generic EpiPen in 2018. This office has now been eliminated

FDA planning for fewer food and drug inspections due to layoffs, officials say Around 170 staff were cut from the FDA's Office of Inspections and Investigations this week as part of wider cuts at U.S. health agencies.

FDA planning for fewer food and drug inspections due to layoffs, officials say

Transcript: Dr. Scott Gottlieb on "Face the Nation with Margaret Brennan," March 23, 2025 The following is the transcript of an interview with Dr. Scott Gottlieb, former FDA commissioner, that aired on "Face the Nation with Margaret Brennan" on March 23, 2025.

My segment on CBSNews.com Face the Nation from Sunday

Transcript: Dr. Scott Gottlieb on "Face the Nation with Margaret Brennan," March 23, 2025 The following is the transcript of an interview with Dr. Scott Gottlieb, former FDA commissioner, that aired on "Face the Nation with Margaret Brennan" on March 23, 2025.

My segment on CBSNews.com Face the Nation from Sunday

I’ll be on Face the Nation tomorrow discussing the latest developments in healthcare policy

YouTube video by CNBC Television Former FDA Commissioner Dr. Scott Gottlieb on solutions to stop the bird flu outbreak

My segment today on cnbc.com on Trump Administration’s new plan to improve biosecurity on poultry farms to reduce outbreaks of avian influenza, and additional steps we may take to mitigate risk as wild birds return to migratory flyways this spring

RFK Jr.'s comments on vitamin A and cod liver oil as treatments for measles are "extremely damaging because the impression it leaves to consumers is that there is a treatment available for measles, when in fact there is not," former FDA head @scottgottliebmd.bsky.social says at #STATBreakthrough:

How to protect the American egg supply from avian flu The most effective strategy against bird flu on chicken farms is prevention, writes former FDA Commissioner Scott Gottlieb — and that may include vaccinating chicks.

My op ed in STAT News on bird flu, egg shortages, vaccines, and FDA regulation — and additional steps we can take ahead of the spring migration season, when wild birds return to North American flighways, and the risk of outbreaks in poultry farms may rise